 Dara Aisner
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 62 | 2023 | 2220 | 5.130 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 41 | 2023 | 968 | 3.720 |
Why?
| | Genetic Testing | 9 | 2022 | 389 | 2.560 |
Why?
| | Pathology, Molecular | 7 | 2019 | 25 | 2.240 |
Why?
| | ErbB Receptors | 19 | 2023 | 569 | 2.200 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 181 | 2.130 |
Why?
| | Mutation | 37 | 2023 | 3457 | 1.950 |
Why?
| | High-Throughput Nucleotide Sequencing | 13 | 2023 | 453 | 1.830 |
Why?
| | Protein Kinase Inhibitors | 24 | 2023 | 811 | 1.790 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 95 | 1.740 |
Why?
| | Neoplasms | 12 | 2023 | 2179 | 1.570 |
Why?
| | Proto-Oncogene Proteins B-raf | 13 | 2022 | 202 | 1.550 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 618 | 1.500 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 407 | 1.450 |
Why?
| | Biomarkers, Tumor | 16 | 2021 | 1059 | 1.250 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 229 | 1.190 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 154 | 1.190 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 237 | 1.150 |
Why?
| | Antineoplastic Agents | 15 | 2019 | 1974 | 1.140 |
Why?
| | Drug Resistance, Neoplasm | 13 | 2023 | 671 | 1.060 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 69 | 1.030 |
Why?
| | Colorectal Neoplasms | 3 | 2022 | 628 | 0.950 |
Why?
| | Gene Rearrangement | 13 | 2019 | 141 | 0.910 |
Why?
| | Adenocarcinoma | 9 | 2018 | 812 | 0.890 |
Why?
| | Brain Neoplasms | 10 | 2018 | 1022 | 0.860 |
Why?
| | Ganglioglioma | 4 | 2014 | 35 | 0.820 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 381 | 0.790 |
Why?
| | Molecular Targeted Therapy | 10 | 2018 | 356 | 0.790 |
Why?
| | Precision Medicine | 4 | 2018 | 363 | 0.740 |
Why?
| | Pyrazoles | 10 | 2018 | 363 | 0.720 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 59 | 0.720 |
Why?
| | Biological Products | 1 | 2022 | 170 | 0.710 |
Why?
| | Humans | 115 | 2023 | 118972 | 0.710 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 88 | 0.700 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 4 | 0.700 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 15 | 0.700 |
Why?
| | Astrocytoma | 3 | 2015 | 113 | 0.680 |
Why?
| | Insurance Coverage | 1 | 2020 | 208 | 0.660 |
Why?
| | Prognosis | 12 | 2019 | 3443 | 0.640 |
Why?
| | Neoplasm Metastasis | 9 | 2022 | 544 | 0.640 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 310 | 0.630 |
Why?
| | Laboratory Proficiency Testing | 2 | 2023 | 5 | 0.630 |
Why?
| | Computational Biology | 4 | 2023 | 588 | 0.620 |
Why?
| | RNA | 5 | 2019 | 833 | 0.560 |
Why?
| | Immunohistochemistry | 9 | 2019 | 1691 | 0.520 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 83 | 0.510 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 455 | 0.500 |
Why?
| | Smoking | 3 | 2018 | 1487 | 0.480 |
Why?
| | ras Proteins | 5 | 2015 | 141 | 0.480 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 900 | 0.470 |
Why?
| | Pyridines | 8 | 2016 | 440 | 0.470 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 178 | 0.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1390 | 0.440 |
Why?
| | Aged, 80 and over | 15 | 2020 | 6561 | 0.420 |
Why?
| | Neoplasm Staging | 11 | 2018 | 1223 | 0.410 |
Why?
| | Telomerase | 7 | 2002 | 207 | 0.400 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 368 | 0.390 |
Why?
| | S100 Proteins | 2 | 2014 | 35 | 0.390 |
Why?
| | Male | 48 | 2022 | 57801 | 0.390 |
Why?
| | Female | 48 | 2023 | 61564 | 0.380 |
Why?
| | Aged | 27 | 2020 | 19657 | 0.370 |
Why?
| | Genomics | 4 | 2023 | 706 | 0.370 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 360 | 0.350 |
Why?
| | Middle Aged | 35 | 2022 | 27617 | 0.350 |
Why?
| | Sulfones | 3 | 2015 | 98 | 0.350 |
Why?
| | Glycine | 3 | 2015 | 162 | 0.350 |
Why?
| | Curriculum | 1 | 2016 | 910 | 0.350 |
Why?
| | Pyrimidines | 3 | 2018 | 382 | 0.340 |
Why?
| | Laboratories | 2 | 2023 | 97 | 0.340 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 81 | 0.320 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 471 | 0.310 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 56 | 0.300 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 80 | 0.300 |
Why?
| | Oncogene Fusion | 2 | 2019 | 9 | 0.300 |
Why?
| | Exons | 5 | 2019 | 307 | 0.290 |
Why?
| | Gene Dosage | 2 | 2018 | 136 | 0.290 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 52 | 0.290 |
Why?
| | Melanoma | 2 | 2020 | 664 | 0.290 |
Why?
| | Treatment Outcome | 11 | 2019 | 9342 | 0.280 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 156 | 0.280 |
Why?
| | Adult | 30 | 2022 | 31512 | 0.280 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2023 | 341 | 0.270 |
Why?
| | Oncogenes | 3 | 2016 | 111 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2275 | 0.270 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 9 | 0.260 |
Why?
| | Immunotherapy | 5 | 2022 | 493 | 0.260 |
Why?
| | Receptor, ErbB-2 | 4 | 2022 | 320 | 0.260 |
Why?
| | Epithelioid Cells | 2 | 2015 | 8 | 0.260 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.240 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1795 | 0.230 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 2851 | 0.230 |
Why?
| | Mesothelioma | 1 | 2023 | 32 | 0.230 |
Why?
| | Survival Analysis | 4 | 2021 | 1267 | 0.230 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 7 | 0.220 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 610 | 0.220 |
Why?
| | Pathologists | 2 | 2023 | 15 | 0.220 |
Why?
| | Goals | 1 | 2023 | 167 | 0.210 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 69 | 0.210 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 133 | 0.210 |
Why?
| | Gene Fusion | 2 | 2018 | 18 | 0.210 |
Why?
| | Young Adult | 12 | 2019 | 10793 | 0.210 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 60 | 0.200 |
Why?
| | Patient Selection | 4 | 2018 | 676 | 0.200 |
Why?
| | Cell Proliferation | 7 | 2017 | 2275 | 0.200 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 31 | 0.200 |
Why?
| | Glioblastoma | 2 | 2015 | 262 | 0.200 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 216 | 0.200 |
Why?
| | Pheochromocytoma | 1 | 2022 | 54 | 0.200 |
Why?
| | Trastuzumab | 1 | 2021 | 92 | 0.200 |
Why?
| | Carbazoles | 1 | 2021 | 80 | 0.200 |
Why?
| | Biopsy | 4 | 2018 | 1079 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1166 | 0.190 |
Why?
| | Meningioma | 1 | 2022 | 82 | 0.190 |
Why?
| | United States | 9 | 2020 | 12555 | 0.190 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 333 | 0.190 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 13 | 0.190 |
Why?
| | Pathology, Clinical | 2 | 2017 | 31 | 0.190 |
Why?
| | Government Regulation | 1 | 2020 | 47 | 0.180 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 69 | 0.180 |
Why?
| | Piperidines | 1 | 2021 | 171 | 0.180 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 202 | 0.180 |
Why?
| | Stakeholder Participation | 1 | 2020 | 69 | 0.180 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 136 | 0.170 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 52 | 0.170 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 317 | 0.170 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 27 | 0.170 |
Why?
| | Smad4 Protein | 1 | 2019 | 37 | 0.170 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 48 | 0.170 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 56 | 0.170 |
Why?
| | Acrylamides | 2 | 2017 | 42 | 0.170 |
Why?
| | Pregnancy Complications | 1 | 2023 | 448 | 0.170 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 31 | 0.160 |
Why?
| | Multigene Family | 1 | 2019 | 200 | 0.160 |
Why?
| | Pyridazines | 1 | 2018 | 50 | 0.160 |
Why?
| | Genetic Markers | 1 | 2019 | 348 | 0.160 |
Why?
| | Piperazines | 2 | 2018 | 316 | 0.160 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 565 | 0.160 |
Why?
| | Database Management Systems | 1 | 2018 | 56 | 0.160 |
Why?
| | Thromboembolism | 1 | 2018 | 99 | 0.160 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 28 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 197 | 0.160 |
Why?
| | Gene Frequency | 1 | 2019 | 513 | 0.160 |
Why?
| | Genetic Association Studies | 1 | 2019 | 371 | 0.150 |
Why?
| | Quinazolines | 3 | 2014 | 245 | 0.150 |
Why?
| | Skin Neoplasms | 2 | 2020 | 762 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2022 | 420 | 0.150 |
Why?
| | Intraoperative Care | 1 | 2017 | 39 | 0.150 |
Why?
| | Smokers | 1 | 2018 | 149 | 0.150 |
Why?
| | Indoles | 2 | 2017 | 316 | 0.150 |
Why?
| | Imidazoles | 1 | 2018 | 232 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.150 |
Why?
| | Gene Deletion | 1 | 2019 | 361 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.150 |
Why?
| | Medical Informatics | 1 | 2018 | 102 | 0.150 |
Why?
| | Chloroquine | 1 | 2017 | 64 | 0.140 |
Why?
| | Coculture Techniques | 1 | 2017 | 208 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 80 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 278 | 0.140 |
Why?
| | Sulfonamides | 2 | 2017 | 445 | 0.140 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 15 | 0.140 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 18 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2017 | 182 | 0.140 |
Why?
| | RNA, Messenger | 4 | 2018 | 2657 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 164 | 0.140 |
Why?
| | Liver Neoplasms | 3 | 2015 | 527 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 64 | 0.140 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 53 | 0.140 |
Why?
| | Codon | 1 | 2016 | 89 | 0.140 |
Why?
| | Immunity, Humoral | 1 | 2016 | 117 | 0.140 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 62 | 0.140 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 71 | 0.130 |
Why?
| | Signal Transduction | 5 | 2017 | 4709 | 0.130 |
Why?
| | Oncogene Proteins | 1 | 2015 | 52 | 0.130 |
Why?
| | Medical Oncology | 3 | 2023 | 229 | 0.130 |
Why?
| | Protein Kinases | 1 | 2017 | 310 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 89 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2016 | 287 | 0.130 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 276 | 0.130 |
Why?
| | Medicare | 1 | 2020 | 663 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1440 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 409 | 0.130 |
Why?
| | Hamartoma | 1 | 2015 | 20 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2016 | 270 | 0.130 |
Why?
| | Pharmacogenetics | 1 | 2016 | 151 | 0.130 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 8 | 0.120 |
Why?
| | Deoxycytidine | 1 | 2015 | 136 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 926 | 0.120 |
Why?
| | DNA Copy Number Variations | 4 | 2018 | 167 | 0.120 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 42 | 0.120 |
Why?
| | Alternative Splicing | 3 | 2017 | 193 | 0.120 |
Why?
| | Lung Transplantation | 1 | 2016 | 263 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2015 | 100 | 0.120 |
Why?
| | Paresis | 1 | 2014 | 31 | 0.120 |
Why?
| | Speech Disorders | 1 | 2014 | 35 | 0.120 |
Why?
| | Health Care Surveys | 1 | 2016 | 546 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2020 | 1055 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 298 | 0.120 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1012 | 0.120 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 150 | 0.120 |
Why?
| | Receptor, trkA | 1 | 2013 | 20 | 0.120 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 874 | 0.120 |
Why?
| | Sarcoma | 1 | 2015 | 137 | 0.120 |
Why?
| | Retrospective Studies | 9 | 2019 | 12978 | 0.120 |
Why?
| | Microscopy, Electron | 1 | 2014 | 413 | 0.120 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 77 | 0.120 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 105 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 1945 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1167 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 298 | 0.110 |
Why?
| | Autophagy | 1 | 2017 | 315 | 0.110 |
Why?
| | Graft Rejection | 1 | 2016 | 555 | 0.110 |
Why?
| | Societies, Medical | 4 | 2018 | 703 | 0.110 |
Why?
| | Headache | 1 | 2014 | 128 | 0.110 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 90 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2015 | 199 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 982 | 0.110 |
Why?
| | Tissue Fixation | 1 | 2012 | 32 | 0.110 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 188 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1868 | 0.110 |
Why?
| | Gene Amplification | 3 | 2019 | 97 | 0.110 |
Why?
| | Disease Progression | 5 | 2018 | 2490 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 653 | 0.110 |
Why?
| | Lung | 4 | 2015 | 3664 | 0.100 |
Why?
| | Mutation Rate | 1 | 2011 | 25 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 399 | 0.100 |
Why?
| | Algorithms | 1 | 2019 | 1541 | 0.100 |
Why?
| | Translocation, Genetic | 1 | 2012 | 92 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2436 | 0.100 |
Why?
| | Specimen Handling | 1 | 2012 | 165 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2017 | 963 | 0.100 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 191 | 0.100 |
Why?
| | Teratoma | 1 | 2011 | 92 | 0.100 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 80 | 0.100 |
Why?
| | Terminology as Topic | 1 | 2012 | 211 | 0.090 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1346 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1965 | 0.090 |
Why?
| | Genome, Human | 1 | 2012 | 387 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 740 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2012 | 286 | 0.090 |
Why?
| | Survival Rate | 4 | 2019 | 1720 | 0.090 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 195 | 0.090 |
Why?
| | Phosphorylation | 1 | 2014 | 1633 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 66 | 0.090 |
Why?
| | Telomere | 3 | 2000 | 204 | 0.090 |
Why?
| | Disease-Free Survival | 3 | 2016 | 649 | 0.090 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 13 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 25 | 0.080 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 734 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1384 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4596 | 0.080 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 185 | 0.080 |
Why?
| | Adolescent | 6 | 2019 | 18480 | 0.080 |
Why?
| | Heart Neoplasms | 1 | 2008 | 50 | 0.080 |
Why?
| | DNA | 1 | 2014 | 1388 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2874 | 0.070 |
Why?
| | Workflow | 2 | 2017 | 148 | 0.070 |
Why?
| | Prospective Studies | 1 | 2017 | 6471 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 1001 | 0.070 |
Why?
| | Eye Neoplasms | 1 | 2005 | 15 | 0.070 |
Why?
| | Mental Disorders | 1 | 2014 | 939 | 0.070 |
Why?
| | Immunophenotyping | 1 | 2005 | 278 | 0.060 |
Why?
| | Administration, Oral | 2 | 2018 | 756 | 0.060 |
Why?
| | Peritoneum | 1 | 2023 | 36 | 0.060 |
Why?
| | Genes, ras | 2 | 2015 | 95 | 0.060 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 333 | 0.060 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 34 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3174 | 0.050 |
Why?
| | Blotting, Western | 4 | 2015 | 1194 | 0.050 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 47 | 0.050 |
Why?
| | Cell Cycle | 2 | 2012 | 550 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1047 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 113 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 969 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 355 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 290 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1597 | 0.050 |
Why?
| | Models, Molecular | 2 | 2018 | 1435 | 0.050 |
Why?
| | Standard of Care | 1 | 2020 | 63 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 454 | 0.040 |
Why?
| | Base Sequence | 3 | 2017 | 2159 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 408 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 690 | 0.040 |
Why?
| | Catalytic Domain | 4 | 2000 | 206 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 6412 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 45 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 580 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 171 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5116 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 52 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 32 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 107 | 0.040 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 27 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2707 | 0.040 |
Why?
| | RNA, Untranslated | 1 | 1999 | 115 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 47 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 540 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 99 | 0.040 |
Why?
| | Breast | 1 | 2018 | 140 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 21 | 0.040 |
Why?
| | Child | 5 | 2015 | 19129 | 0.040 |
Why?
| | Diarrhea | 1 | 2018 | 181 | 0.040 |
Why?
| | A549 Cells | 1 | 2017 | 48 | 0.040 |
Why?
| | Quality Control | 1 | 2017 | 159 | 0.040 |
Why?
| | Pathology, Surgical | 1 | 2016 | 8 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 522 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2017 | 71 | 0.040 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2871 | 0.040 |
Why?
| | Fatigue | 1 | 2018 | 297 | 0.040 |
Why?
| | Centrosome | 1 | 2016 | 59 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 339 | 0.030 |
Why?
| | Carcinoma | 2 | 2012 | 204 | 0.030 |
Why?
| | Child, Preschool | 3 | 2015 | 9491 | 0.030 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 5 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1323 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 18 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 534 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 39 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 663 | 0.030 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 136 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 116 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 67 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 83 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1474 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 625 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 254 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 755 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 667 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 131 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 975 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 194 | 0.030 |
Why?
| | Animals | 5 | 2019 | 33381 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 13 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 219 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 369 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 173 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 736 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2013 | 101 | 0.030 |
Why?
| | Syndecan-4 | 1 | 2012 | 7 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 571 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1244 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 420 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 756 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2015 | 408 | 0.030 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 17 | 0.030 |
Why?
| | Bone and Bones | 1 | 2015 | 289 | 0.030 |
Why?
| | Incidence | 1 | 2018 | 2424 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2015 | 312 | 0.030 |
Why?
| | Mice | 2 | 2019 | 15520 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 5690 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 103 | 0.020 |
Why?
| | Infant | 2 | 2015 | 8293 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 307 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 395 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 394 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2012 | 247 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 827 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 265 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 89 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 17 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 529 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1781 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2062 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1203 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 823 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4077 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 302 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 5 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2513 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 23 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 533 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1774 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 780 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 115 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1094 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3003 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3588 | 0.020 |
Why?
| | Fibroblasts | 2 | 2000 | 842 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2484 | 0.020 |
Why?
| | Transcription Factors | 1 | 2011 | 1570 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 5255 | 0.010 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 5 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 19 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 96 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 41 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 20 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 268 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 211 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 11 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 47 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 44 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 173 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 888 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 174 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 174 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 147 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 401 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 161 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 439 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1308 | 0.010 |
Why?
| | Skin | 1 | 2000 | 657 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1085 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 940 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|